Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells

Endocrine-Related Cancer

Volumn 20, Issue 5, 2013, Pages 659-667

  Gild, Matti L ^a   Landa, Iñigo ^a   Ryder, Mabel ^a,b   Ghossein, Ronald A ^c   Knauf, Jeffrey A ^a   Fagin, James A ^a,b  

^a Human Oncology and Pathogenesis Program   (United States)

^b Department of Medicine ^*  (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Drug combinations; Medullary thyroid carcinoma; MTOR; MTOR inhibitors; Oncogenic RET; RET inhibitors

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL GROWTH; CELL MUTANT; CELL ONCOGENE; CONTROLLED STUDY; GROWTH INHIBITION; MOUSE; NONHUMAN; ONCOGENE RET; SIGNAL TRANSDUCTION; TARGET CELL; THYROID CELL; THYROID MEDULLARY CARCINOMA;

EID: 84886391134     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0085     Document Type: Article

References (24)

1. Airaksinen MS & Saarma M 2002 The GDNF family: signalling, biological functions and therapeutic value. Nature Reviews. Neuroscience 3 383-394. (doi:10.1038/nrn812)
2. Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, Stephan C, Grosios K, Wartmann M, Cozens R et al. 2007 The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Research 67 6956-6964. (doi:10.1158/0008-5472. CAN-06-4605)
3. Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M & Nelkin BD 2007 Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. Journal of Clinical Endocrinology and Metabolism 92 4712-4718. (doi:10.1210/jc.2007-1184)
4. Castellone MD & Santoro M 2008 Dysregulated RET signaling in thyroid cancer. Endocrinology and Metabolism Clinics of North America 37 363-374, viii. (doi:10.1016/j.ecl.2008.02.006)
5. Couderc C, Poncet G, Villaume K, Blanc M, Gadot N, Walter T, Lepinasse F, Hervieu V, Cordier-Bussat M, Scoazec JY et al. 2011 Targeting the PI3K/mTOR pathway in murine endocrine cell lines: in vitro and in vivo effects on tumor cell growth. American Journal of Pathology 178 336-344. (doi:10.1016/j.ajpath. 2010.11.023)
6. Dadon T, Ball D & Nelkin BD 2013 Misidentification of putative medullary thyroid cancer cell lines RO-H85-1 and RO-D81-1. Journal of Clinical Endocrinology and Metabolism 98 954-955. (doi:10.1210/jc.2012-4181)
7. de Groot JW, Links TP, Plukker JT, Lips CJ & Hofstra RM 2006 RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocrine Reviews 27 535-560. (doi:10.1210/er.2006-0017)
8. Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y, Gorshtein A, Praiss M, Kendler E, Feinmesser R, Grossman AB & Shimon I 2010 The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells. Molecular and Cellular Endocrinology 315 87-94. (doi:10.1016/j.mce.2009.09.027)
9. Jin N, Jiang T, Rosen DM, Nelkin BD & Ball DW 2011 Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clinical Cancer Research 17 6482-6489. (doi:10.1158/1078-0432.CCR- 11-0933)
10. Koh YW, Shah MH, Agarwal K, McCarty SK, Koo BS, Brendel VJ, Wang C, Porter K, Jarjoura D, Saji M et al. 2012 Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. Endocrine-Related Cancer 19 29-38. (doi:10.1530/ERC-11-0155)
11. Kunnimalaiyaan M, Ndiaye M & Chen H 2006 Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery 140 1009-1014 (discussion 1014-1005) (doi:10.1016/j.surg.2006.06.040)
12. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F et al. 2011 Activity of XL184 (Cabozantinib) , an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. Journal of Clinical Oncology 29 2660-2666. (doi:10.1200/JCO. 2010.32.4145)
13. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV et al. 2010 Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. Journal of Clinical Oncology 28 2323-2330. (doi:10.1200/JCO.2009.25.0068)
14. Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA & Fagin JA 2008 BRAFV600E mutation is associated with preferential sensitivity to mitogenactivated protein kinase kinase inhibition in thyroid cancer cell lines. Journal of Clinical Endocrinology and Metabolism 93 2194-2201. (doi:10.1210/jc.2007-2825)
15. Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB, Zhang Y, Liu Y, Sacco A, Ngo H et al. 2011 Defining the role of TORC1/2 in multiple myeloma. Blood 118 6860-6870. (doi:10.1182/blood-2011-03-342394)
16. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G et al. 2010 Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. Journal of Clinical Oncology 28 245-255. (doi:10.1200/JCO.2008.21.5988)
17. Powell DJ Jr, Russell J, Nibu K, Li G, Rhee E, Liao M, Goldstein M, Keane WM, Santoro M, Fusco A et al. 1998 The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Research 58 5523-5528.
18. Rapa I, Saggiorato E, Giachino D, Palestini N, Orlandi F, Papotti M & Volante M 2011 Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 96 2146-2153. (doi:10.1210/jc.2010-2655)
19. Robinson BG, Paz-Ares L, Krebs A, Vasselli J & Haddad R 2010 Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 95 2664-2671. (doi:10.1210/jc.2009-2461)
20. Samadi AK, Bazzill J, Zhang X, Gallagher R, Zhang H, Gollapudi R, Kindscher K, Timmermann B & Cohen MS 2012 Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway. Surgery 152 1238-1247. (doi:10.1016/j.surg.2012.08.031)
21. Sarbassov DD, Guertin DA, Ali SM & Sabatini DM 2005 Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 1098-1101. (doi:10.1126/science.1106148)
22. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC et al. 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. Journal of Clinical Endocrinology and Metabolism 93 4331-4341. (doi:10.1210/jc.2008-1102)
23. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR et al. 2012 Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 30 134-141. (doi:10.1200/JCO.2011.35.5040)
24. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG et al. 2011 Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 364 514-523. (doi:10.1056/NEJMoa1009290)